Ckd Bio (063160) - Total Liabilities
Based on the latest financial reports, Ckd Bio (063160) has total liabilities worth ₩173.38 Billion KRW (≈ $117.50 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Ckd Bio annual equity growth to track the company's year-over-year net asset growth rate.
Ckd Bio - Total Liabilities Trend (2008–2025)
This chart illustrates how Ckd Bio's total liabilities have evolved over time, based on quarterly financial data. See Ckd Bio (063160) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Ckd Bio Competitors by Total Liabilities
The table below lists competitors of Ckd Bio ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Immutep Ltd
AU:IMM
|
Australia | AU$13.35 Million |
|
SIL Investments Limited
NSE:SILINV
|
India | Rs2.27 Billion |
|
CTI Traffic Industries Co Ltd
TWO:2230
|
Taiwan | NT$695.62 Million |
|
Taiwan Alpha Electronic Co Ltd
TWO:6204
|
Taiwan | NT$157.31 Million |
|
Facephi Biometria SA
MC:FACE
|
Spain | €26.22 Million |
|
Korea Parts & Fasteners Co.Ltd
KQ:024880
|
Korea | ₩356.28 Billion |
|
SKB Shutters Corporation Bhd
KLSE:7115
|
Malaysia | RM142.01 Million |
|
Mondi PLC
LSE:MNDI
|
UK | GBX4.95 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down Ckd Bio's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Ckd Bio worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ckd Bio's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ckd Bio (2008–2025)
The table below shows the annual total liabilities of Ckd Bio from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩172.83 Billion ≈ $117.13 Million |
+12.61% |
| 2024-12-31 | ₩153.48 Billion ≈ $104.01 Million |
-10.12% |
| 2023-12-31 | ₩170.76 Billion ≈ $115.72 Million |
+3.62% |
| 2022-12-31 | ₩164.79 Billion ≈ $111.68 Million |
+20.24% |
| 2021-12-31 | ₩137.05 Billion ≈ $92.88 Million |
+19.47% |
| 2020-12-31 | ₩114.71 Billion ≈ $77.74 Million |
+53.19% |
| 2019-12-31 | ₩74.88 Billion ≈ $50.75 Million |
+103.17% |
| 2018-12-31 | ₩36.86 Billion ≈ $24.98 Million |
-1.55% |
| 2017-12-31 | ₩37.44 Billion ≈ $25.37 Million |
-18.17% |
| 2016-12-31 | ₩45.75 Billion ≈ $31.00 Million |
+5.73% |
| 2015-12-31 | ₩43.27 Billion ≈ $29.32 Million |
+0.10% |
| 2014-12-31 | ₩43.22 Billion ≈ $29.29 Million |
-16.27% |
| 2013-12-31 | ₩51.62 Billion ≈ $34.99 Million |
-15.75% |
| 2012-12-31 | ₩61.28 Billion ≈ $41.53 Million |
-22.72% |
| 2011-12-31 | ₩79.29 Billion ≈ $53.73 Million |
+88.21% |
| 2010-12-31 | ₩42.13 Billion ≈ $28.55 Million |
-10.72% |
| 2009-12-31 | ₩47.18 Billion ≈ $31.98 Million |
+3.25% |
| 2008-12-31 | ₩45.70 Billion ≈ $30.97 Million |
-- |
About Ckd Bio
CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also e… Read more